In ₹ Crore except Per Share Latest Annual	ALKEM FY26	MANKIND FY26	TORNTPHARM FY26	IPCALAB FY26	Peer Average
Valuation — at last close
P/E	◆ 26.38×	53.28×	71.65×	42.82×	55.92× -53%
P/B	◆ 4.39×	6.25×	18.48×	6.06×	10.26× -57%
EV/EBITDA	◆ 20.10×	29.44×	38.82×	25.19×	31.15× -35%
Market Cap	₹60,719 Cr	₹1.02L Cr	₹1.55L Cr	₹48,868 Cr	₹1.02L Cr -40%
Growth
Revenue CAGR 3Y	8.25%	◆ 17.73%	13.27%	15.60%	15.53% -47%
Revenue CAGR 5Y	10.09%	—	11.80%	◆ 12.22%	12.01% -16%
Net Income CAGR 3Y	32.67%	13.96%	19.75%	◆ 35.20%	22.97% +42%
Revenue YoY (latest Q)	10.95%	17.33%	◆ 50.79%	20.76%	29.63% -63%
Net Income YoY (latest Q)	-22.00%	37.67%	-9.64%	◆ 82.18%	36.74% -160%
Profitability
EBITDA Margin	20.43%	25.34%	◆ 32.61%	20.51%	26.15% -22%
Net Income Margin	◆ 15.98%	13.57%	15.29%	12.27%	13.71% +17%
Return on Common Equity	17.84%	12.49%	◆ 27.07%	15.20%	18.25% -2%
Return on Capital Employed	◆ 17.59%	12.51%	14.88%	16.05%	14.48% +21%
Return on Assets	◆ 12.19%	6.94%	7.21%	9.81%	7.99% +53%
Credit & Quality
Total Debt/Equity	0.11×	0.38×	0.84×	◆ 0.07×	0.43× -74%
Interest Coverage	16.32×	4.27×	8.94×	◆ 20.55×	11.25× +45%
Scale — latest FY
Revenue / Total Income	₹14,712 Cr	₹14,278 Cr	₹13,980 Cr	₹9,646 Cr	₹12,635 Cr +16%
Net Income	₹2,351 Cr	₹1,938 Cr	₹2,138 Cr	₹1,184 Cr	₹1,753 Cr +34%
Total Assets	₹20,873 Cr	₹28,080 Cr	₹44,312 Cr	₹12,370 Cr	₹28,254 Cr -26%
EPS	₹192.51	₹46.35	₹63.92	₹44.98	₹51.75 +272%
Book Value per Share	₹1,156.01	₹394.87	₹247.86	₹317.85	₹320.19 +261%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.